Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain leak clue to chronic fatigue and long COVID brain fog?

NCT ID NCT07256795

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Johns Hopkins study looks at whether a leaky blood-brain barrier and immune changes contribute to cognitive problems in people with ME/CFS (chronic fatigue syndrome), both those who got sick before the pandemic and those who developed it after COVID-19. Researchers will use brain scans and blood tests in 200 adults aged 18-70. The goal is to better understand the biology behind brain fog and memory issues in these conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal why many people with ME/CFS or long COVID experience brain fog and memory problems, pointing toward new ways to diagnose or treat these cognitive issues.
What could go wrong
This is an observational study, not a treatment trial. It aims to understand the disease, not test a therapy. Results may not lead directly to new treatments, and findings might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

18-70 years of age * At least 8th grade education * Onset of the following symptoms prior to July 2019 (Pre-SARS-CoV-2 pandemic) and meeting 2015 IOM diagnostic criteria for MECFS:

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion criteria for pre-pandemic onset ME/CFS cohort: * 18-70 years of age * At least 8th grade education * Onset of the following symptoms prior to July 2019 (Pre-SARS-CoV-2 pandemic) and meeting 2015 IOM diagnostic criteria for MECFS: * Substantial reduction in functioning and persistent and profound fatigue for at least 6 months. The person is unable to undertake the same level of activity before they became - . Their fatigue is not the result of significant exertion and is not substantially alleviated by rest. * Post-exertional malaise. * Unrefreshing sleep * At least one of the following two symptoms: * Cognitive impairment (difficulty with memory, finding words, understanding etc). * Orthostatic intolerance (symptoms like palpitations, sweating, dizziness, nausea when standing that are reduced or eliminated when lying down). Inclusion criteria post SARS-CoV-2 onset ME/CFS: * 18-70 years of age * At least 8th grade education * Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the World Health Organization: * Suspected case of SARS-CoV-2 infection * Three options, A through C: Meets the clinical OR epidemiological criteria. * Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. * Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization) C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test. * Probable case of SARS-CoV-2 infection, defined as meets clinical criteria above AND is a contact of a probable or confirmed case or is linked to a COVID-19 cluster. * Confirmed case of SARS-CoV-2 infection - Two options, i. and ii.: * A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or * Meeting clinical criteria AND/OR epidemiological criteria (See suspect case A). With a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test. * Post SARS CoV 2 onset of the following symptoms, meeting 2015 IOM diagnostic criteria for ME/CFS: * Substantial reduction in functioning and persistent and profound fatigue for at least 6 months. The person is unable to undertake the same level of activity before they became - - Their fatigue is not the result of significant exertion and is not substantially alleviated by rest. * Post-exertional malaise. * Unrefreshing sleep. * At least one of the following two symptoms: * Cognitive impairment (difficulty with memory, finding words, understanding etc). * Orthostatic intolerance (symptoms like palpitations, sweating, dizziness, nausea when standing that are reduced or eliminated when lying down). * Given that our application focuses on MECFS patients with neuropsychiatric symptoms the investigators will require participants to report \>1 symptom with at least one of the symptoms being neuropsychiatric in nature (e.g., brain fog, anxiety, depression, headaches). Exclusion both groups (pre-pandemic onset ME/CFS and post SARS-CoV-2 onset ME/CFS): * History of Axis I psychiatric disorders (including alcohol and drug dependence) except for mood disorders which developed after onset of ME/CFS symptoms. * Severe or unstable medical condition that would interfere with physical participation. * Neurological disorders, such as stroke, epilepsy, multiple sclerosis, Parkinson's disease, or dementia. * History of severe head injury that resulted in persistent traumatic brain injury sequelae. * Any condition that is contraindicated for the MRI environment (e.g., metal in the body, pacemaker, claustrophobia) * Currently pregnant. * Lack of English proficiency (to ensure validity in verbal outcome measures) * Active or recent (within 3 months) substance misuse (which is known to affect BBB permeability) assessed by clinical interview and toxicology (nicotine/cannabis allowed) * History of psychosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic fatigue syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21297, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.